Cognitive Behavioral Therapy for Patient With Rheumatoid Arthritis and Obesity

de Oliveira Ribeiro, Natalia Pinho; de Mello Schier, Alexandre Rafael; Marinho, Tamires; Machado, Sergio; Nardi, Antonio Egidio; Silva, Adriana Cardoso
December 2013
Journal of Medical Cases;2013, Vol. 4 Issue 7, p443
Academic Journal
Rheumatoid arthritis is an autoimmune disease that causes physical and psychological symptoms when patients are not monitored; these symptoms include depression, anxiety and even the risk of suicide. This study is a case report of one female patient who has Rheumatoid arthritis, and obesity. The present study was carried out with a multidisciplinary approach (physician and psychologist) and included psychological evaluations and cognitive behavioral therapy (CBT) after a hospital stay when the patient suffered changes in her general framework with a worsening of her disease. The CBT was effective in reducing the patient's depression and anxiety. In addition, the CBT reduced the patient's dysfunctional beliefs, extinguished the thoughts of suicide and taught her to better control her emotions, which reduced her daily peaks of physical pain, making them more affordable than before. CBT increased the patient's motivation, which led to an improvement in her condition and better adherence to treatment. The CBT was effective in treating an obese patient with rheumatoid arthritis who did not want to adhere to the treatment. This suggests that CBT can be an excellent tool for the treatment of chronic and autoimmune diseases; however, further studies are needed with more subjects.


Related Articles

  • Erratum to: Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. Nakagomi, Daiki; Ikeda, Kei; Kawashima, Hirotoshi; Kobayashi, Yoshihisa; Suto, Akira; Nakajima, Hiroshi // Rheumatology International;Oct2013, Vol. 33 Issue 10, p2707 

    A correction to the article "Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases" which was published in the September 11, 2013 issue is presented.

  • Head-to-head study with RA drugs.  // Australian Journal of Pharmacy;Jul2013, Vol. 94 Issue 1118, p30 

    The article focuses on the study ADalimumab ACTemrA (ADACTA)", which was published in the periodical "The Lancet," reveals that Actemra offers improvement in the signs and symptoms of rheumatoid arthritis (RA) for patients who require monotherapy as compared to adalimumab, as of July 1, 2013.

  • Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Dcodhar, S. D.; Sethi, R.; Srimal, R. C. // Indian Journal of Medical Research;Jul2013, Vol. 138 Issue 1, p632 

    A short term, double blind, cross-over study was carried out in 18 patients with 'definite' rheumatoid arthritis to compare the antirheumatic activity of curcumin (diferuloyl methane) 1200 mg/day with phenylbutazone 300 mg/day. Subjective and objective assessment in patients who were not taking...

  • Efficacy of certolizumab pegol: a case study in a patient with rheumatoid arthritis on maintenance hemodialysis. Nishimura, Akito; Minegishi, Yohjiroh; Kwamura, Keiko; Ichino, Asako; Uchiyama, Katsufumi // Rheumatology International;Sep2015, Vol. 35 Issue 9, p1601 

    The article presents a case study of a 63-year-old woman who was diagnosed nephritis in her twenties and had polyarticular pain in her earlier. It mentions that she was diagnosed with rheumatoid arthritis (RA). Etanercept (ETN) was administrated as prednisolone did not improve her disease...

  • Methotrexate.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p195 

    An abstract of the article "Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report" by H. Shimada and others is presented.

  • Genentech's ACTEMRA(r) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article presents information on the ADACTA (ADalimumab ACTemrA) study according to which patients receiving ACTEMRA® (tocilizumab) experienced more decrease in disease activity after 24 weeks than those who were given adalimumab monotherapy. It is further mentioned that ADACTA study...

  • Short-Term Efficacy and Safety of Leflunomide in the Treatment of Active Rheumatoid Arthritis in Everyday Clinical Use. Minh Nguyen; Marmar Kabir, D.; Ravaud, Philippe // Clinical Drug Investigation;2004, Vol. 24 Issue 2, p103 

    Objective: To determine the efficacy and safety profile of 6-month treatment with leflunomide 20mg daily in patients with acute rheumatoid arthritis (RA) receiving treatment from 197 office-based rheumatologists in France. Methods: This open-label, prospective, multicentre study included 378...

  • Importancia de los aspectos nutricionales en el proceso inflamatorio de pacientes con artritis reumatoide; una revisión. González Cernadas, Leticia; Rodríguez-Romero, Beatriz; Carballo-Costa, Lidia // Nutricion Hospitalaria;feb2014, Vol. 29 Issue 2, p237 

    Introduction: Clinical characteristics of rheumatoid arthritis (AR) justify its multidisciplinary approach, within which nutritional intervention is included. Certain nutritional components influence the cellular metabolism and interfere in the pathological inflammatory process, so that they may...

  • Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. Nakashima, Yasuharu; Kondo, Masakazu; Fukuda, Takaaki; Harada, Hiroshi; Horiuchi, Takahiko; Ishinishi, Takashi; Jojima, Hiroshi; Kuroda, Koji; Miyahara, Hisaaki; Maekawa, Masayuki; Nishizaka, Hiroaki; Nagamine, Ryuji; Nakashima, Hitoshi; Otsuka, Takeshi; Shono, Eisuke; Suematsu, Eiichi; Shimauchi, Takashi; Tsuru, Tomomi; Wada, Ken; Yoshizawa, Shigeru // Modern Rheumatology;Mar2014, Vol. 24 Issue 2, p258 

    Objectives. This study aimed to evaluate the remission in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ), based on prospectively registered data in clinical practice. Methods. We studied 114 consecutive RA patients treated with TCZ for an average of 3.5 years. Remission was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics